000282304 001__ 282304
000282304 005__ 20251117142809.0
000282304 0247_ $$2doi$$a10.1007/s00406-023-01751-2
000282304 0247_ $$2pmid$$apmid:38316685
000282304 0247_ $$2ISSN$$a1433-8491
000282304 0247_ $$2ISSN$$a0003-9373
000282304 037__ $$aDZNE-2025-01274
000282304 041__ $$aEnglish
000282304 082__ $$a610
000282304 1001_ $$0P:(DE-2719)9003591$$aMarcos Morgado, Barbara$$b0$$udzne
000282304 245__ $$aAssessment of immunoprecipitation with subsequent immunoassays for the blood-based diagnosis of Alzheimer's disease.
000282304 260__ $$aHeidelberg$$bSpringer$$c2024
000282304 3367_ $$2DRIVER$$aarticle
000282304 3367_ $$2DataCite$$aOutput Types/Journal article
000282304 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1763385981_17166
000282304 3367_ $$2BibTeX$$aARTICLE
000282304 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000282304 3367_ $$00$$2EndNote$$aJournal Article
000282304 500__ $$aISSN 1433-8491 not unique: **2 hits**.
000282304 520__ $$aThe Aβ42/40 ratio and the concentration of phosphorylated Tau181 in blood plasma represent attractive biomarkers for Alzheimer's disease. As a means for reducing potential matrix effects, which may interfere with plasma immunoassays, we have previously developed a pre-analytical sample workup by semi-automated immunoprecipitation. Here we test the compatibility of pre-analytical immunoprecipitations with automated Aβ1-40, Aβ1-42 and phosphorylated Tau181 immunoassays on the Lumipulse platform and compare the diagnostic performance of the respective immunoprecipitation immunoassay approaches with direct plasma measurements. 71 participants were dichotomized according to their Aβ42/40 ratios in cerebrospinal fluid into the diagnostic groups amyloid-positive (n = 32) and amyloid-negative (n = 39). The plasma Aβ1-42/1-40 ratio and phosphorylated Tau181 levels were determined on the Lumipulse G600II platform (Fujirebio) by direct measurements in EDTA-plasma or after Aβ- or Tau-immunoprecipitation, respectively. Pre-analytical immunoprecipitation of Aβ turned out to be compatible with the Lumipulse Aβ assays and resulted in a numerical, yet statistically not significant increase in the area under the ROC curve for plasma Aβ1-42/1-40. Additionally, we observed a significant increase in the standardised effect size (Cohen's D). Pre-analytical immunoprecipitation of Tau resulted in increased differences between the diagnostic groups in terms of median and mean phosphorylated Tau 181 levels. Furthermore, we observed a greater Cohen's d (p < 0.001) and a larger area under the ROC curve (p = 0.038) after Tau-IP. Our preliminary findings in a small, preselected sample indicate that pre-analytical immunoprecipitation may have the potential to improve the diagnostic performance of plasma biomarker immunoassays for Aβ1-42/1-40 and phosphorylated Tau181 to predict brain amyloid deposition.
000282304 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000282304 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000282304 650_7 $$2Other$$aAlzheimer’s disease
000282304 650_7 $$2Other$$aAmyloid beta
000282304 650_7 $$2Other$$aBiomarker
000282304 650_7 $$2Other$$aBlood plasma
000282304 650_7 $$2Other$$aTau
000282304 7001_ $$00000-0002-8672-9032$$aKlafki, Hans-Wolfgang$$b1
000282304 7001_ $$00000-0002-4199-5468$$aBauer, Chris$$b2
000282304 7001_ $$00000-0002-2925-5790$$aWaniek, Katharina$$b3
000282304 7001_ $$00000-0001-5484-9710$$aEsselmann, Hermann$$b4
000282304 7001_ $$00000-0002-4115-0334$$aWirths, Oliver$$b5
000282304 7001_ $$00000-0001-5785-9594$$aHansen, Niels$$b6
000282304 7001_ $$00000-0002-9225-1493$$aLachmann, Ingolf$$b7
000282304 7001_ $$00009-0002-8832-3164$$aOsterloh, Dirk$$b8
000282304 7001_ $$00009-0008-8896-4328$$aSchuchhardt, Johannes$$b9
000282304 7001_ $$0P:(DE-2719)2811317$$aWiltfang, Jens$$b10
000282304 773__ $$0PERI:(DE-600)2793981-9$$a10.1007/s00406-023-01751-2$$p-$$tArchiv für Psychiatrie und Nervenkrankheiten$$vAdvance online publication$$x1433-8491$$y2024
000282304 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9003591$$aExternal Institute$$b0$$kExtern
000282304 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811317$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b10$$kDZNE
000282304 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000282304 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-05
000282304 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-05
000282304 9201_ $$0I:(DE-2719)1410006$$kAG Wiltfang$$lMolecular biomarkers for predictive diagnostics of neurodegenerative diseases$$x0
000282304 980__ $$ajournal
000282304 980__ $$aEDITORS
000282304 980__ $$aVDBINPRINT
000282304 980__ $$aI:(DE-2719)1410006
000282304 980__ $$aUNRESTRICTED